Targeted proteomics in Alzheimer's disease: focus on amyloid-beta (Q37157835)

18 August 2017

1 reference

title

Targeted proteomics in Alzheimer's disease: focus on amyloid-beta (English)

1 reference

18 August 2017

0 references

2

Henrik Zetterberg

1 reference

18 August 2017

5

Kaj Blennow

1 reference

18 August 2017

1

Erik Portelius

1 reference

18 August 2017

4

Ulf Andreasson

1 reference

18 August 2017

Johan Gobom

3

1 reference

18 August 2017

publication date

1 April 2008

1 reference

Expert Review of Proteomics

18 August 2017

published in

1 reference

18 August 2017

volume

5

1 reference

18 August 2017

issue

2

1 reference

18 August 2017

page(s)

225-237

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

18 August 2017

1 reference

Amyloid deposition as the central event in the aetiology of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Purification and cloning of amyloid precursor protein beta-secretase from human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Abeta 17-42 in Alzheimer's disease activates JNK and caspase-8 leading to neuronal apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Proteolytic degradation of the amyloid beta-protein: the forgotten side of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Functional role of the low-density lipoprotein receptor-related protein in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

LRP-mediated clearance of Abeta is inhibited by KPI-containing isoforms of APP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Amyloid plaque core protein in Alzheimer disease and Down syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Alzheimer's disease: a dysfunction of the amyloid precursor protein(1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Vicious cycles within the neuropathophysiologic mechanisms of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Axonal transport and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Amyloid-beta vaccination: testing the amyloid hypothesis?: heads we win, tails you lose!

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

The state versus amyloid-beta: the trial of the most wanted criminal in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Amyloid beta-peptide is produced by cultured cells during normal metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

CSF markers for incipient Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Cerebrospinal fluid markers for prediction of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Biomarkers of Alzheimer disease in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Amyloid beta1-40 quantification in CSF: comparison between chromatographic and immunochemical methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Amyloid-beta(1-42) rapidly forms protofibrils and oligomers by distinct pathways in low concentrations of sodium dodecylsulfate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Oxidative stress in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

A specific amyloid-beta protein assembly in the brain impairs memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Lipocalin-type prostaglandin D synthase/beta-trace is a major amyloid beta-chaperone in human cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Coupling immunoaffinity techniques with MS for quantitative analysis of low-abundance protein biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Mass spectrometric immunoassay

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Characterization of beta-amyloid peptide from human cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

The role of cholesterol in the biosynthesis of beta-amyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Cerebrospinal fluid profile of amyloid beta peptides in patients with Alzheimer's disease determined by protein biochip technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Aspects of beta-amyloid as a biomarker for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

"Secretase," Alzheimer amyloid protein precursor secreting enzyme is not sequence-specific

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Beta-amyloid precursor protein cleavage by a membrane-bound protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Proteolysis of A beta peptide from Alzheimer disease brain by gelatinase A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Comparative proteomics based on stable isotope labeling and affinity selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Dynamics of protein turnover, a missing dimension in proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

A proteomic method for the analysis of changes in protein concentrations in response to systemic perturbations using metabolic incorporation of stable isotopes and mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

The Alzheimer's disease neuroimaging initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Disease-modifying therapies for Alzheimer disease: challenges to early intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta ); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Identification of a beta-secretase activity, which truncates amyloid beta-peptide after its presenilin-dependent generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

BACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

Cerebrospinal fluid amyloidβ peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloidβ peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.5.2.225

21 January 2018

Identifiers

DOI

10.1586/14789450.5.2.225

1 reference

18 August 2017

1 reference